Tapestry (TPR) Emerges as a Leading Idea in Telsey’s 2026 Outlook

Tapestry, Inc. (NYSE:TPR) is included among the 20 Best Performing Dividend Stocks in 2025.

On December 17, Telsey Advisory raised its price target on Tapestry, Inc. (NYSE:TPR) to $150 from $125 and kept an Outperform rating. The call came as the firm shared its outlook and top picks for 2026. Telsey named Tapestry as a leading idea across Specialty, Luxury, and Beauty, pointing to how the company is navigating tariffs and continuing to operate from a position of strength.

That optimism sits alongside a more cautious message from management earlier in November. At the time, Tapestry, Inc. (NYSE:TPR) lifted its full-year targets but guided holiday-quarter earnings below expectations. Like many retailers, the company is moving carefully as tariffs and uneven consumer spending cloud the outlook during a critical shopping season.

On an earnings call, CFO Scott Roe said the company is deliberately keeping expectations in check. He noted that tariffs could create some profit volatility throughout the year. Tapestry, Inc. (NYSE:TPR) projected second-quarter earnings of about $2.15 per share, slightly below the $2.17 consensus estimate, according to LSEG data. Tariffs remain a pressure point. Tapestry sources products from India, Vietnam, and Cambodia, all affected by higher US tariffs. Even so, the company has avoided raising prices. CEO Joanne Crevoiserat told Reuters that strong demand for higher-margin Tabby bags, priced up to $750, has helped absorb those costs.

The company is also leaning more heavily into international growth. Sales in China rebounded to 19% during the quarter, while Europe recorded a 32% increase, showing renewed traction outside North America.

Tapestry, Inc. (NYSE:TPR) is a global luxury fashion holding company that owns brands including Coach, Kate Spade New York, and Stuart Weitzman. It sells handbags, footwear, apparel, and accessories through retail stores, e-commerce platforms, and wholesale channels.

READ NEXT: 14 Best Pharma Dividend Stocks to Buy in 2026 and 14 Best Dividend Aristocrats to Invest in Heading into 2026.

Disclosure: None.